Exogenous lipid clearance in compensated liver cirrhosis. 1986

M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli

The tolerance to exogenous fats has been evaluated in patients with liver cirrhosis. A three-stage lipid clearance test with continuous infusion (3 hr) of a triglyceride emulsion, Intralipid, was performed on 10 patients with well compensated liver cirrhosis and 10 normolipidemic volunteers. During the infusion, blood samples were collected for the measurement of particulate triglycerides (TG) by nephelometry; samples were also collected for total TG, free fatty acids (FFA) and free tryptophan (TRP) determinations. Plasma endogenous triglycerides were calculated as the total minus exogenous, particulate, TG. The fractional removal rate (K2) and the maximal clearing capacity (K1) for exogenous TG were lower in patients than in controls, though a significant difference (p less than 0.05) was found only for K1. Endogenous TG and FFA showed a comparable rise in patients and controls during Intralipid infusion. A significant increase in free TRP was noted in cirrhotics upon maximal infusion rate. It is concluded that: in patients with well compensated liver cirrhosis the maximal clearing capacity (K1) for exogenous TG is impaired. Nonetheless, moderate amounts of fat may be removed at a normal rate from the bloodstream; a normal synthesis rate of exogenous TG may be maintained even in a severely damaged liver; considering the possible role of free TRP in the pathogenesis of hepatic encephalopathy (HE), the use of large amounts of lipids should be discouraged in patients with decompensated liver cirrhosis, or even avoided in those with impending or overt HE.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005217 Fat Emulsions, Intravenous Emulsions of fats or lipids used primarily in parenteral feeding. Intravenous Fat Emulsion,Intravenous Lipid Emulsion,Lipid Emulsions, Intravenous,Emulsion, Intravenous Fat,Emulsion, Intravenous Lipid,Emulsions, Intravenous Fat,Emulsions, Intravenous Lipid,Fat Emulsion, Intravenous,Intravenous Fat Emulsions,Intravenous Lipid Emulsions,Lipid Emulsion, Intravenous
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
June 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
April 1984, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
April 2019, Research and practice in thrombosis and haemostasis,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
February 2024, Clinical chemistry and laboratory medicine,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
April 1946, Medicina espanola,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
January 1995, Ryoikibetsu shokogun shirizu,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
March 1971, Klinische Wochenschrift,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
January 1985, International journal of clinical pharmacology research,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
June 2017, Clinical journal of gastroenterology,
M Muscaritoli, and C Cangiano, and A Cascino, and F Ceci, and V Caputo, and P Martino, and P Serra, and F Rossi Fanelli
May 2013, Digestive diseases and sciences,
Copied contents to your clipboard!